Cart
sales@molnova.com
Avotaciclib
CAS No. 1983983-41-0
Avotaciclib( —— )
Catalog No. M35116 CAS No. 1983983-41-0
Avotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 273 | In Stock |
|
| 10MG | 433 | In Stock |
|
| 25MG | 712 | In Stock |
|
| 50MG | 986 | In Stock |
|
| 100MG | 1321 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2651 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAvotaciclib
-
NoteResearch use only, not for human use.
-
Brief DescriptionAvotaciclib (BEY1107) is a potent, orally active cyclin-dependent kinase 1 (CDK1) inhibitor, suitable for research in locally advanced or metastatic pancreatic cancer.
-
DescriptionAvotaciclib (BEY1107) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). Avotaciclib can be used for the research of locally advanced or metastatic pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1983983-41-0
-
Formula Weight281.27
-
Molecular FormulaC13H11N7O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=NC(N)=NC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232.
molnova catalog
related products
-
Roniciclib
A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
-
Indisulam
Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines.
-
Palbociclib hydrochl...
A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.
